AMR Action Fund

A harrowing patient story from the UK of a man who has run out of treatment options for a nasty staph infection and is pursuing phage therapy. “I’ve had numerous pills, potions, antibiotics, transfusions and none of them worked. We have exhausted the available options and are down to phage which was raised as a last resort,” Mr Stocking said. "I am 81 and I can’t pioneer much more with my life so whatever I can do to be of use to anybody then let’s give it a go." #AMR via The Telegraph https://lnkd.in/eDqpZcWn

The threat of drug-resistant fungal infections is growing while investments into innovative anti-fungal diagnostics & therapies are lacking, writes Norman van Rhijn in The Conversation UK. More here: bit.ly/4hhWI78 #AMR

A new Nature study found that rifaximin, an antibiotic commonly used to treat liver disease, causes resistance to daptomycin, one of the few drugs that is effective against vancomycin-resistant enterococcus: https://lnkd.in/d_aRbyZH

Congratulations to TenNor Therapeutics. The company’s lead asset, rifaquizinone, has the potential to become the first new drug developed specifically for Helicobacter pylori infection in more than 30 years. Learn more: https://lnkd.in/exnU7XmV

Sepsis, closely tied to #AMR, is responsible for nearly 14 million deaths each year but remains under-prioritized globally. Tomorrow, Deepali Patel will participate in a discussion exploring policies that integrate efforts to address these twin threats, ensuring stronger health systems and better global health outcomes. Learn more: https://lnkd.in/dNSEwjyH #UNITEGlobalSummit

Four sessions on #AMR tomorrow at the World Health Summit, with the Fund’s Deepali Patel chairing a discussion on innovation and access. Livestream link 👇

It is encouraging to see the G7 once again express its support for “tackling market failures of novel antimicrobial R&D, including through innovative market sustainable approaches.” The group specifically noted that it is reinforcing its “commitment to continue to expedite the urgent implementation of effective pull incentives in our regional and domestic markets and health systems.” Urgency is key. Read the full communique here: https://lnkd.in/e2PXzysy

As WHO notes in the report, of the 32 antibiotics under development to address priority pathogens, only 12 can be considered innovative, and just 4 of these 12 are active against at least one WHO ‘Critical’ pathogen. G7 governments should follow the lead of the UK and implement appropriately sized pull incentives to address the broken market.

Melissa Murray regularly ran 10 km a day—until a serious infection caused her to nearly lose a leg. She had an invasive Group A strep (iGAS) bacterial infection that could not be treated with standard antibiotics and suddenly needed round-the-clock care. Read more via CBC https://t.co/U3hQfjWsix #AMR

ICYMI, the Center for Global Development last week released a new report on the economic consequences of AMR and the findings are staggering. AMR increases the cost of health care by $66 billion. Under certain conditions, AMR health costs could rise to $325 billion and the global economy would be $1.7 trillion smaller in 2050. Learn more and download the full report: https://lnkd.in/eMkHcaWc